In a recent entry for “re:Cycling,” the blog of the Society for Menstrual Cycle Research, journalist Holly Grigg-Spall questions whether the U.S. Food and Drug Administration went far enough in its new labeling requirements for the Yasmin line of birth control pills.
Grigg-Spall points out that the new labels mention the results of “conflicting” studies, most of which concluded that the pills in question cause a significant increase ...
continue reading...
According to an ABC News report, relatively stable women suffering from depression may want to consider going off their antidepressants for the first trimester of a pregnancy, although they should keep in mind that it will take four-to-six weeks for the drug effect to wear off and that the medications should be resumed at the first sign of a relapse.
The report also makes it clear that going ...
continue reading...
A judicial panel has ruled that litigation by multiple parties against Pfizer, Inc., over birth defects allegedly caused by the antidepressant Zoloft, will be transferred to and consolidated in the federal court for the Eastern District of Pennsylvania.
The proceedings will consolidate 57 different actions filed in six federal court districts around the country. In the transfer order released on April 17, members of the judicial ...
continue reading...Amid news of lawsuits concerning the antidepressant Zoloft and the hair-loss drug Propecia, the Judicial Panel on Multidistrict Legislation held a hearing on March 29 in San Diego, California.
The panel of judges meets every two months to consider whether various lawsuits should be consolidated before a single judge for pre-trial proceedings.
Pfizer, the maker of Zoloft, is facing litigation from nearly 90 lawsuits by families who claim their children have suffered birth defects as a result of in utero exposure ...
continue reading...
